Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Morphosys Ag (NASDAQ:MOR) on Thursday, setting a price target of EUR124, which is approximately 1191.42% above the present share price of $11.02.
Shu expects Morphosys Ag to post earnings per share (EPS) of $0.64 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Morphosys Ag, with an average price target of $77.16.
The analysts price targets range from a high of $142.31 to a low of $12.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $38.23 million and a net profit of -$71.36 million. The company's market cap is $1.5 billion.
According to TipRanks.com, Berenberg Bank analyst Zhiqiang Shu is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.1% and a 41.46% success rate.
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery (NASDAQ:DISCA) segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.